Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry
- Conditions
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Children's Hospitals and Clinics of Minnesota
- Target Recruit Count
- 156
- Registration Number
- NCT01464606
- Locations
- 🇺🇸
Anne K Harris, Minneapolis, Minnesota, United States
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 23
- Registration Number
- NCT01446809
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT01331590
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01329900
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT01258634
- Locations
- 🇺🇸
University of Chicago Department of Pediatrics Hematology/Oncology, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 642
- Registration Number
- NCT01231906
- Locations
- 🇺🇸
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸Corewell Health Children's, Royal Oak, Michigan, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2013-08-12
- Target Recruit Count
- 47
- Registration Number
- NCT01172912
- Locations
- 🇮🇹
Fondazione Istituto Nazionale dei Tumori, Milan, Italy
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01169636
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2021-09-13
- Target Recruit Count
- 76
- Registration Number
- NCT01156883
- Locations
- 🇮🇹
Azienda Ospedaliera - Nuovo Ospedale "Torrette", Ancona, Italy
🇮🇹USL 8 - Ospedale S.Donato, Arezzo, Italy
🇮🇹UO Ematologia con trapianto- AOU Policlinico Consorziale di Bari, Bari, Italy
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: PEG-L-asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: mercaptopurineDrug: ifosfamideDrug: methotrexateDrug: vincristine sulfateDrug: prednisoneRadiation: Radiation TherapyDrug: thioguanineDrug: vindesineDrug: daunoxomeDrug: fludarabine
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 6136
- Registration Number
- NCT01117441
- Locations
- 🇦🇹
A.oe. Landeskrankenhaus Klagenfurt, Abt. für Kinder- und Jugendheilkunde, Klagenfurt, Austria
🇨🇿University Hospital Brno, Department of Pediatric Oncology, Brno, Czechia
🇩🇪Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.